By identifying specific targets influencing lipid metabolism and cardiovascular-related diseases, the present review highlights the role of MerTK in NAFLD-associated atherosclerotic lesions as a potential innovative therapeutic target. This evidence concerns the gene MERTK and metabolic dysfunction-associated steatotic liver disease.